Effect of Coenzyme Q10 in mitigating oxidative DNA damage in Down syndrome patients, a double blind randomized controlled trial

• Published in: Neurobiology of aging Vol. 32; no. 11; pp. 2103 - 2105
• Main Authors: Tiano, L, Carnevali, P, Padella, L, Santoro, L, Principi, F, Brugè, F, Carle, F, Gesuita, R, Gabrielli, O, Littarru, G.P
• Format: Journal Article
• Language: English
• Published: London Elsevier Inc 01.11.2011; Elsevier
• Subjects: Adult; Biological and medical sciences; Chromosome aberrations; Coenzyme Q10; Comet assay; Development. Senescence. Regeneration. Transplantation; DNA Damage - drug effects; Double-Blind Method; Down syndrome; Down Syndrome - drug therapy; Down Syndrome - metabolism; Fundamental and applied biological sciences. Psychology; Humans; Internal Medicine; Medical genetics; Medical sciences; Neurology; Oxidative DNA damage; Oxidative Stress - drug effects; Treatment Outcome; Ubiquinone - analogs & derivatives; Ubiquinone - pharmacology; Ubiquinone - therapeutic use; Vertebrates: nervous system and sense organs; Down syndrome; Coenzyme Q 10; Comet assay; Oxidative DNA damage; Coenzyme Q10; Chromosomal aberration; Human; Trisomy; Senescence; DNA; Aneuploidy; Coenzyme
• ISSN: 0197-4580; 1558-1497
• DOI: 10.1016/j.neurobiolaging.2009.11.016

Abstract Down syndrome (DS) is a chromosomal abnormality (trisomy 21) associated with a complex phenotype. Oxidative stress is known to play a major role in this pathology both due to genetic and epigenetic factors, suggesting that oxidative imbalance contributes to the clinical manifestation of DS. In particular, the implications of oxidative DNA damage in Down syndrome has been linked with neurodegeneration. Here we report the results of a double blind controlled trial aimed at investigating the protective effect of Coenzyme Q10 on DNA oxidation in this clinical setting using the single cell gel electrophoresis technique.